Css LLC Il Trims Stock Position in Pfizer Inc. (NYSE:PFE)

Css LLC Il reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 41.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 30,859 shares of the biopharmaceutical company's stock after selling 22,240 shares during the quarter. Css LLC Il's holdings in Pfizer were worth $819,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Tallon Kerry Patrick purchased a new position in Pfizer during the fourth quarter worth about $509,000. Diversify Wealth Management LLC lifted its holdings in shares of Pfizer by 13.9% in the 4th quarter. Diversify Wealth Management LLC now owns 10,750 shares of the biopharmaceutical company's stock valued at $287,000 after buying an additional 1,308 shares during the period. Pure Financial Advisors LLC boosted its stake in shares of Pfizer by 13.4% in the fourth quarter. Pure Financial Advisors LLC now owns 24,966 shares of the biopharmaceutical company's stock valued at $662,000 after buying an additional 2,945 shares in the last quarter. Royal Fund Management LLC grew its holdings in Pfizer by 192.0% during the fourth quarter. Royal Fund Management LLC now owns 24,713 shares of the biopharmaceutical company's stock worth $656,000 after acquiring an additional 16,249 shares during the period. Finally, Lmcg Investments LLC raised its position in Pfizer by 7.3% in the fourth quarter. Lmcg Investments LLC now owns 55,974 shares of the biopharmaceutical company's stock worth $1,485,000 after acquiring an additional 3,804 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on PFE. Cantor Fitzgerald began coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price target on the stock. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. UBS Group upped their price target on Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Stock Performance

Pfizer stock opened at $23.06 on Thursday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $31.54. The company has a market capitalization of $131.10 billion, a price-to-earnings ratio of 16.35, a PEG ratio of 0.64 and a beta of 0.58. The stock has a fifty day moving average of $23.50 and a two-hundred day moving average of $25.25. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion during the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.82 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.46%. The ex-dividend date is Friday, May 9th. Pfizer's dividend payout ratio is presently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.